NexPoint Real Estate Finance, Inc. is a commercial mortgage real estate investment trust (REIT). The Company is primarily focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties and common equity investments, as well as multifamily and single-family commercial mortgage-backed securities securitizations, promissory notes, revolving credit facilities and stock warrants. The Company’s primary investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. It intends to achieve this objective primarily by originating, structuring and investing in its target assets. It primarily focuses on investments in the real estate sectors, including in the multifamily, SFR, self-storage and life science sectors, predominantly in the metropolitan statistical areas (MSAs). Its business is conducted through NexPoint Real Estate Finance Operating Partnership, L.P.
Company Information
About this company
Key people
James David Dondero
Chairman of the Board, President
Paul Richards
Chief Financial Officer, Executive Vice President - Finance, Treasurer, Assistant Secretary
Matthew Ryan Mcgraner
Executive Vice President, Chief Investment Officer
Dennis Charles Sauter
General Counsel, Secretary
Scott F. Kavanaugh
Lead Independent Director
Brian D. Mitts
Director
Edward Constantino
Independent Director
Arthur B. Laffer
Independent Director
Carol Swain
Independent Director
Click to see more
Key facts
- Shares in issue17.72m
- EPICNREF
- ISINUS65342V1017
- LocationUnited States
- SectorServices
- IndustryRental & Leasing
- Market cap$265.12m
- Employees1
- ExchangeNew York Stock Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.